New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
April 29, 2014
07:23 EDTBMYBristol-Myers acquires iPerian for $175M
Bristol-Myers Squibb and iPierian announced Bristol-Myers Squibb has acquired iPierian, a privately held biotechnology company focused on the discovery and development of new treatments for Tauopathies. The acquisition gives Bristol-Myers Squibb full rights to iPierianís asset IPN007, a preclinical monoclonal antibody that represents a new approach to treat progressive supranuclear palsy and other Tauopathies, and has the potential to commence Phase 1 clinical trials by early FY15. Under the terms of the agreement, Bristol-Myers Squibb has acquired all of iPierianís issued and outstanding shares of capital stock and all common stock equivalents in an all cash transaction for a purchase price of $175M, with the potential for additional development and regulatory milestone payments totaling $550M, along with future royalties on net sales. The transaction is expected to be accounted for as an asset acquisition for Bristol-Myers Squibb resulting in a $175M charge during 2Q14.
News For BMY From The Last 14 Days
Check below for free stories on BMY the last two weeks.
Sign up for a free trial to see the rest of the stories you've been missing.
September 17, 2014
07:43 EDTBMYBofA/Merrill to hold a conference
Subscribe for More Information
September 16, 2014
06:00 EDTBMYBristol-Myers announces Health Canada approval of Yervoy
Subscribe for More Information

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use